APA

Penka M., Schwarz J., Ovesná P., Cervinek L., Dulíček P., Pospíšilová D., Kissová J. & Pavlík T. (20151016). [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012]. : Vnitrni lekarstvi.

Chicago

Penka M, Schwarz J, Ovesná P, Cervinek L, Dulíček P, Pospíšilová D, Kissová J and Pavlík T. 20151016. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012]. : Vnitrni lekarstvi.

Harvard

Penka M., Schwarz J., Ovesná P., Cervinek L., Dulíček P., Pospíšilová D., Kissová J. and Pavlík T. (20151016). [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012]. : Vnitrni lekarstvi.

MLA

Penka M, Schwarz J, Ovesná P, Cervinek L, Dulíček P, Pospíšilová D, Kissová J and Pavlík T. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012]. : Vnitrni lekarstvi. 20151016.